Verastem Inc. (VSTM)

8.44
0.23 2.65
NASDAQ : Health Technology
Prev Close 8.67
Open 8.71
Day Low/High 8.10 / 9.07
52 Wk Low/High 2.05 / 8.81
Volume 5.78M
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 73.39M
Market Cap 629.71M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insiders Seeing Green With VSTM At New 52-Week High

Insiders Seeing Green With VSTM At New 52-Week High

In trading on Friday, shares of Verastem Inc touched a new 52-week high of $6.61/share. That's a 244.27% rise, or $4.69 per share from the 52-week low of $1.92 set back on 06/16/2017.

Verastem Oncology Announces $43.0 Million Offering Of Common Stock

Verastem Oncology Announces $43.0 Million Offering Of Common Stock

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced a registered sale to funds managed...

Verastem Oncology And Yakult Honsha Co., Ltd. Sign Exclusive License Agreement For The Development And Commercialization Of Duvelisib In Japan

Verastem Oncology And Yakult Honsha Co., Ltd. Sign Exclusive License Agreement For The Development And Commercialization Of Duvelisib In Japan

Verastem, Inc. (President and CEO: Robert Forrester)(NASDAQ:VSTM) and Yakult Honsha Co.

Verastem Oncology Presents Data On Two Lead Drug Candidates At ASCO 2018 Annual Meeting

Verastem Oncology Presents Data On Two Lead Drug Candidates At ASCO 2018 Annual Meeting

Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the presentation of five...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq: VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to fourteen new employees to purchase an aggregate of 405,000 shares...

Verastem Oncology Announces Closing Of Underwriter's Option To Purchase Additional Shares

Verastem Oncology Announces Closing Of Underwriter's Option To Purchase Additional Shares

Verastem, Inc., (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has issued 1,166,666 shares of the Company's common...

First Week Of VSTM July 20th Options Trading

Investors in Verastem Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Verastem Oncology To Present Scientific Data Supporting Immuno-Oncology Applications Of Duvelisib & Defactinib At The 3rd Annual Advances In Immuno-Oncology Congress

Verastem Oncology To Present Scientific Data Supporting Immuno-Oncology Applications Of Duvelisib & Defactinib At The 3rd Annual Advances In Immuno-Oncology Congress

Verastem, Inc. (NASDAQ: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that Jonathan Pachter, PhD, the Company's Chief Scientific...

Verastem Oncology To Present Duvelisib Data At EHA 2018 Annual Meeting

Verastem Oncology To Present Duvelisib Data At EHA 2018 Annual Meeting

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the selection of four abstracts for oral and poster...

Verastem Oncology To Present Data On Two Lead Drug Candidates At ASCO 2018 Annual Meeting

Verastem Oncology To Present Data On Two Lead Drug Candidates At ASCO 2018 Annual Meeting

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that five abstracts have been...

Verastem Oncology Announces Pricing Of Public Offering Of Common Stock

Verastem Oncology Announces Pricing Of Public Offering Of Common Stock

Verastem, Inc., (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its registered underwritten public offering...

Verastem Oncology Announces Public Offering Of Common Stock

Verastem Oncology Announces Public Offering Of Common Stock

Verastem, Inc. (NASDAQ: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has commenced a registered underwritten public...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq: VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to ten new employees to purchase an aggregate of 209,000 shares of...

Verastem Oncology Reports First Quarter 2018 Financial Results

Verastem Oncology Reports First Quarter 2018 Financial Results

Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the quarter ended March 31, 2018 and...

Verastem Oncology Reports On Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma And Follicular Lymphoma Opportunity, Landscape And Advancements In Pre-Commercial Initiatives At Analyst And Investor Day

Verastem Oncology Reports On Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma And Follicular Lymphoma Opportunity, Landscape And Advancements In Pre-Commercial Initiatives At Analyst And Investor Day

Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, yesterday hosted in New York City an Analyst and Investor Day, titled,...

First Week Of December 21st Options Trading For Verastem (VSTM)

Investors in Verastem Inc saw new options become available this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Verastem To Host Analyst And Investor Day On May 2, 2018

Verastem To Host Analyst And Investor Day On May 2, 2018

Verastem, Inc. (NASDAQ: VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it will host an Analyst and Investor Day titled, "Duvelisib: Harnessing the Power of Dual...

Verastem To Present At The H.C. Wainwright Global Life Sciences Conference

Verastem To Present At The H.C. Wainwright Global Life Sciences Conference

Verastem, Inc. (NASDAQ: VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.

Verastem Updates Presentation Time For Oppenheimer & Co. Healthcare Conference

Verastem Updates Presentation Time For Oppenheimer & Co. Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 28th Annual Oppenheimer...

Verastem To Present At Upcoming Conferences

Verastem To Present At Upcoming Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following investor...

Verastem Reports Year-End 2017 Financial Results

Verastem Reports Year-End 2017 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the year ended December 31, 2017 and...

Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to eight new employees to purchase an...

Verastem To Present At The 30th Annual ROTH Conference

Verastem To Present At The 30th Annual ROTH Conference

Verastem, Inc. (NASDAQ:VSTM), focused on developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 30 th Annual ROTH Conference on Monday, March...

Verastem Submits New Drug Application To U.S. FDA For Duvelisib For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma And Follicular Lymphoma

Verastem Submits New Drug Application To U.S. FDA For Duvelisib For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma And Follicular Lymphoma

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced it has submitted a New Drug Application (NDA) to the U.

Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an...

Verastem Presents Preclinical Data At ASCO-SITC Highlighting The Synergistic Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

Verastem Presents Preclinical Data At ASCO-SITC Highlighting The Synergistic Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that a poster highlighting the synergistic effects of duvelisib in...

Verastem Announces Increased Hercules Debt Facility

Verastem Announces Increased Hercules Debt Facility

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced its entry into an amendment to its Loan and Security Agreement with...

Verastem Appoints Joseph Lobacki As Chief Commercial Officer

Verastem Appoints Joseph Lobacki As Chief Commercial Officer

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Joseph Lobacki as Executive Vice President and...